Autoantibodies in the diagnosis and management of liver disease

Journal of Clinical Gastroenterology

Volumn 37, Issue 4, 2003, Pages 315-329

  Czaja, Albert J ^a   Norman, Gary L ^b  

^a MAYO CLINIC   (United States)

^b INOVA DIAGNOSTICS INC   (United States)

Author keywords

Autoantibodies; Autoimmune hepatitis; Autoimmunity; Liver disease

Indexed keywords

ANTINUCLEAR ANTIBODY; ASIALOGLYCOPROTEIN; AUTOANTIBODY; DOUBLE STRANDED DNA; ENDOMYSIUM ANTIBODY; LIVER ANTIGEN; MITOCHONDRION ANTIBODY; SMOOTH MUSCLE ANTIBODY;

ANTIBODY DETECTION; ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHROMATIN; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DIAGNOSTIC TEST; HUMAN; KIDNEY MICROSOME; LIVER DISEASE; LIVER INJURY; LIVER MICROSOME; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SACCHAROMYCES CEREVISIAE;

AUTOANTIBODIES; HUMANS; LIVER DISEASES; PROGNOSIS;

EID: 0141678206     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200310000-00011     Document Type: Review

References (145)

1. Rose NR. Fundamental concepts of autoimmunity and autoimmune disease. In: Krawitt EL, Wiesner RH, Nishioka M, eds. Autoimmune Liver Diseases, 2nd ed. New York: Elsevier Science Publishers; 1998:1-20.
2. Schindler LW. Understanding the Immune System. In: NIH Publication 92-529. Bethesda: U.S. Department of Health and Human Services; 1991:15-18.
3. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol. 2001;96:1224-1231.
4. Doherty DG, Penzotti JE, Koelle DM, et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol. 1998;161:3527-3535.
5. Czaja AJ. Autoantibodies. Bailliere's Clin Gastroenterol. 1995;9:723-744.
6. Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology. 2001;120:239-249.
7. Senecal J-L, Ichiki S, Girard D, et al. Autoantibodies to nuclear lamins and to intermediate filament proteins: natural, pathologic or pathogenic? J Rheumatol. 1993;20:211-219.
8. Tomer Y, Shoenfeld Y. The significance of natural autoantibodies. Immunol Invest. 1988;17:389-424.
9. Diaw L, Magnac C, Pritsch O, et al. Structural and affinity studies of IgM polyreactive natural autoantibodies. J Immunol. 1997;158:968-976.
10. Casali P, Schettino EW. Structure and function of natural antibodies. Curr Top Microbiol Immunol. 1999;210:167-179.
11. Hayakawa K, Asano M, Shinton SA, et al. Positive selection of natural autoreactive B cells. Science. 1999;285:113-116.
12. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394-401.
13. Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol. 1995;90:1206-1211.
14. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479-497.
15. Czaja AJ, Nishioka M, Morshed SA, et al. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology. 1994;107:200-207.
16. Czaja AJ, Carpenter HA, Santrach PJ, et al. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology. 1993;18:816-822.
17. Czaja AJ, Carpenter HA, Santrach PJ, et al. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology. 1995; 108:157-164.
18. Czaja AJ, Carpenter HA, Santrach PJ, et al. Significance of human leukocyte antigens DR3 AND DR4 in chronic viral hepatitis. Dig Dis Sci. 1995;40:2098-2106.
19. Czaja AJ, Carpenter HA, Santrach PJ, et al. Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol. 1996;24:52-59.
20. Czaja AJ, Dos Santos RM, Porto A, et al. Immune phenotype of chronic liver disease. Dig Dis Sci. 1998;43:2149-2155.
21. Czaja AJ, Carpenter HA, Santrach PJ, et al. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol. 1998;29: 198-206.
22. Czaja AJ, Cassani F, Cataleta M, et al. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci. 1997;42:1688-1696.
23. Homburger HA, Cahen YD, Griffiths J, et al. Detection of antinuclear antibodies. Comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med. 1998;122: 993-999.
24. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997;40:1601-1611.
25. Kurki P, Miettinen A, Linder E, et al. Different types of smooth muscle antibodies in chronic active hepatitis and primary biliary cirrhosis: their diagnostic and prognostic significance. Gut. 1980;21:878-884.
26. Pedersen JS, Toh BH, Mackay IR, et al. Segregation of autoantibody to cytoskeletal filaments, actin and intermediate filaments with two types of chronic active hepatitis. Clin Exp Immunol. 1982;48:527-532.
27. Kurki P, Miettinen A, Salaspuro M, et al. Cytoskeleton antibodies in chronic active hepatitis, primary biliary cirrhosis, and alcoholic liver disease. Hepatology. 1983;3:297-302.
28. Toh B-H. Smooth muscle autoantibody and autoantigens. Clin Exp Immunol. 1979;38:621-628.
29. Czaja AJ, Cassani F, Cataleta M, et al. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology. 1996; 24:1068-1073.
30. Manns MP, Johnson EF, Griffin KJ, et al. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest. 1989;83:1066-1072.
31. Manns MP, Griffin KJ, Sullivan KF, et al. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest. 1991;88:1370-1378.
32. Yamamoto AM, Cresteil D, Homberg JC, et al. Characterization of the anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology. 1993;104:1762-1767.
33. Homberg J-C, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology. 1987;7:1333-1339.
34. Reddy KR, Krawitt EL, Homberg JC, et al. Absence of anti-LKM1 antibody in hepatitis C viral infection in the United States of America. J Viral Hepat. 1995;2:175-179.
35. Gerotto M, Pontisso P, Giostra F, et al. Analysis of the hepatitis C virus genome in patients with anti-LKM-1 autoantibodies. J Hepatol. 1994; 21:273-276.
36. Durazzo M, Philipp T, van Pelt FNAM, et al. Heterogeneity of microsomal autoantibodies (LKM) in chronic hepatitis C and D virus infection. Gastroenterology. 1995;108:455-462.
37. Manns M, Zanger U, Gerken G, et al. Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo. Hepatology. 1990; 12:127-132.
38. Lohr H, Manns M, Kyriatsoulis A, et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol. 1991;84:297-302.
39. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology. 1992;103:1290-1295.
40. Clemente MG, Obermayer-Straub P, Meloni A, et al. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab. 1997;82:1353-1361.
41. Aaltonen J, Borses P, Sandkuijl L, et al. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type 1 assigned to chromosome 21. Nat Genet. 1994;8:83-87.
42. Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet. 1997;17:393-398.
43. Clemente MG, Meloni A, Obermayer-Staub P, et al. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology. 1998;114:324-328.
44. Obermayer-Straub P, Perheentupa J, Braun S, et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasisectodermal dystrophy. Gastroenterology. 2001;121:668-677.
45. Van de Water J, Cooper A, Surh CD, et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med. 1989;320:1377-1380.
46. Fregeau DR, Davis PA, Danner DJ, et al. Antimitochondrial antibodies of primary biliary cirrhosis recognize dihydrolipoamide acyltransferase and inhibit enzyme function of the branched chain alpha-ketoacid dehydrogenase complex. J Immunol. 1989;142:3815-3820.
47. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology. 1993;105:1522-1528.
48. Mutimer DJ, Fussey SPM, Yeaman SJ, et al. Frequency of IgG and IgM autoantibodies to the four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. Hepatology. 1989;10:403-407.
49. Michieletti P, Wanless IR, Katz A, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut. 1994;35:260-265.
50. Heseltine L, Turner IB, Fussey SPM, et al. Primary biliary cirrhosis. Quantitation of autoantibodies to purified mitochondrial enzymes and correlation with disease progression. Gastroenterology. 1990;99:1786-1792.
51. Berg PA, Klein R. Antimitochondrial antibodies in primary biliary cirrhosis. A clue to its etiopathogenesis? J Hepatol. 1992;15:6-9.
52. Moteki S, Leung PS, Coppel RL, et al. Use of a designer triple expression hybrid clone for three different lipoyl domains for the detection of antimitochondrial antibodies. Hepatology. 1996;24:97-103.
53. Fritzler MJ, Manns MP. Anti-mitochondrial autoantibodies. Clin Appl Immunol Rev. 2002;3:87-113.
54. Vergani D, Bogdanos DP. Positive markers in AMA-negative PBC. Am J Gastroenterol. 2003;98:241-243.
55. Miyakawa H, Tanaka A, Kikuchi K, et al. Detection of antimitochondrial autoantibodies in immunofluescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology. 2001;34:243-248.
56. Duerr RH, Targan SR, Landers CJ, et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1991;100:1385-1391.
57. Hagen EC, Ballieux BEPB, van Es LA, et al. Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences. Blood. 1993;81:1996-2002.
58. Mulder AHL, Horst G, Haagsma EB, et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology. 1993;17:411-417.
59. Bansi D, Chapman R, Fleming K. Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass. J Hepatol. 1996;24:581-586.
60. Targan SR, Landers C, Vidrich A, et al. High-titer antineutrophil cytoplasmic antibodies in type 1 autoimmune hepatitis. Gastroenterology. 1995;108:1159-1166.
61. LaBrecque DR, Phillips MJP, Ippolito LA, et al. Antineutrophil cytoplasmic antibody and chronic liver disease. (abstract) Hepatology. 1999; 30:428A.
62. Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and type 2 autoimmune hepatitis. Hepatology. 1997;25:1105-1107.
63. Terjung B, Herzog V, Worman HJ, et al. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology. 1998;28:332-340.
64. Terjung B, Spengler U, Sauerbruch T, et al. Atypical p-ANCA in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology. 2000; 119:310-322.
65. Bardella MT, Fraquelli M, Quatrini M, et al. Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet. Hepatology. 1995;22:833-836.
66. Kaukinen K, Halme L, Collin P, et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology. 2002;122:881-888.
67. Volta U, Rodrigo L, Granito A, et al. Celiac disease in autoimmune cholestatic liver disorders. Am J Gastroenterol. 2002;97:2609-2613.
68. Sedlack RE, Smyrk TC, Czaja AJ, et al. Celiac-disease-associated autoimmune cholangitis. Am J Gastroenterol. 2002;97:3196-3198.
69. Volta U, Granito A, De Franceschi L, et al. Anti tissue transglutaminase antibodies as predictors of silent coeliac disease in patients with hypertransaminasaemia of unknown origin. Dig Liver Dis. 2001;33:420-425.
70. Kingham JGC, Parker DR. The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut. 1998;42: 120-122.
71. Volta U, De Franceshi L, Molinaro N, et al. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci. 1998;43:2190-2195.
72. Hay JE, Wiesner RH, Shorter RG, et al. Primary sclerosing cholangitis and celiac disease. A novel association. Ann Intern Med. 1988;109:713-717.
73. Guandalini S, Gupta P. Celiac disease. A diagnostic challenge with many facets. Clin Appl Immunol Rev. 2002;2:293-305.
74. James MW, Scott BB. Endomysial antibody in the diagnosis and management of coeliac disease. Postgrad Med J. 2000;76:466-468.
75. Chorzelski TP, Sulej T, Tchorzewski H, et al. IgA class endomysium antibodies in dermatitis herpetiformis and coeliac disease. Ann N Y Acad Sci. 1983;420:325-334.
76. Corraccio A, Cavataio F, Iacono G, et al. IgA antiendomysial antibodies on the umbilical cord in diagnosing celiac disease. Scand J Gastroenterol. 1996;31:759-763.
77. Dieterich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 1997;3:797-801.
78. Lock RJ, Pitcher MCL, Unsworth DJ. IgA anti-tissue transglutaminase as a diagnostic marker of gluten sensitive enteropathy. J Clin Pathol. 1999;52:274-277.
79. Hansson T, Dahlbom I, Hall J, et al. Antibody reactivity against human and guinea pig tissue transglutaminase in children with celiac disease. J Pediatr Gastroenterol Nutr. 2000;30:379-384.
80. Leon F, Camarero C, Pena R, et al. Anti-transglutaminase IgA ELISA: clinical potential and drawbacks in celiac disease diagnosis. Scand J Gastroenterol. 2001;36:849-853.
81. Wong RC, Wilson RJ, Steele RH, et al. A comparison of 13 guinea pig and human anti-tissue transglutaminase antibody ELISA kits. J Clin Pathol. 2002;55:488-494.
82. Carroccio A, Giannitrapani L, Soresi M, et al. Guinea pig transglutaminase immunolinked assay does not predict coeliac disease in patients with chronic liver disease. Gut. 2001;49:506-511.
83. Dieterich W, Laag E, Schopper H, et al. Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterology. 1998;115: 1317-1321.
84. Jaskowski TD, Schroder C, Martins TB, et al. IgA antibodies against endomysium and transglutaminase: a comparison of methods. J Clin Lab Anal. 2001;15:108-111.
85. Biagi F, Pezzimenti D, Campanella J, et al. Endomysial and tissue transglutaminase antibodies in coeliac sera: a comparison not influenced by previous serological testing. Scand J Gastroenterol. 2001;35:955-958.
86. Cummins A, Thompson F. Sensitivity of anti-endomysial antibody in detecting celiac disease. Gastroenterology. 2002;122:246-247.
87. Gomez JC, Selvaggio G, Pizarro B, et al. Value of a screening algorithm for celiac disease using tissue transglutaminase antibodies as first level in a population-based study. Am J Gastroenterol. 2002;97:2785-2790.
88. Horvath K, Hill ID. Anti-tissue transglutaminase antibody as the first line screening for celiac disease: good-bye antigliadin tests? Am J Gastroenterol. 2002;97:2702-2704.
89. Doenecke D, Albig W, Bode C, et al. Histones: genetic diversity and tissue-specific gene expression. Histochem Cell Biol. 1997;107:1-10.
90. Czaja AJ, Ming C, Shirai M, et al. Frequency and significance of antibodies to histones in autoimmune hepatitis. J Hepatol. 1995;23:32-38.
91. Chen M, Shirai M, Czaja AJ, et al. Characterization of anti-histone antibodies in patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 1998;13:483-489.
92. Wood JR, Czaja AJ, Beaver SJ, et al. Frequency and significance of antibody to double-stranded DNA in chronic active hepatitis. Hepatology. 1986;6:976-980.
93. Czaja AJ, Morshed SA, Parveen S, et al. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology. 1997;26:567-572.
94. Gurian LE, Rogoff TM, Ware AJ, et al. The immunologic diagnosis of chronic active "autoimmune" hepatitis: distinction from systemic lupus erythematosus. Hepatology. 1985;5:397-402.
95. Lidman K, Biberfield G, Fagraeus A, et al. Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol. 1976;24:266-272.
96. Czaja AJ, Cassani F, Cataleta M, et al. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology. 1996; 24:1068-1073.
97. Fusconi M, Cassani F, Zauli D, et al. Anti-actin antibodies: a new test for an old problem. J Immunol Methods. 1990;130:1-8.
98. Cancado ELR, Vilas-Boas LS, Abrantes-Lemos CP, et al. Heat serum inactivation as a mandatory procedure for antiactin antibody detection in cell culture. Hepatologyy. 1996;23:1098-1104.
99. (Ser)Sec complex recognized by autoantibodies from patients with type 1 autoimmune hepatitis. Clin Exp Immunol. 2000;121:364-374.
100. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardized SLA/ LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51:259-264.
101. Manns M, Gerken G, Kyriatsoulis A, et al. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987;1:292-294.
102. Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology. 1993;18:1-9.
103. Kanzler S, Weidemann C, Gerken G, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol. 1999;31:635-640.
104. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors in type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:413-419.
105. Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity. 2002;35:475-483.
106. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002;35:658-664.
107. McFarlane IG, McFarlane BM, Major GN, et al. Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol. 1984;55: 347-354.
108. McFarlane BM, McSorley CG, McFarlane IG, et al. Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor (hepatic lectin) in acute and chronic liver disorders. J Hepatol. 1986;3:196-205.
109. Treichel U, Poralla T, Hess G, et al. Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. Hepatology. 1990;11:606-612.
110. Poralla T, Treichel U, Lohr H, et al. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis. 1991;11: 215-222.
111. Czaja AJ, Pfeifer KD, Decker RH, et al. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci. 1996;41:1733-1740.
112. McFarlane IG, Hegarty JE, McSorley CG, et al. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet. 1984;2:954-956.
113. Lapierre P, Hajoui O, Homberg J-C, et al. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology. 1999;116:643-649.
114. Muratori L, Sztul E, Muratori P, et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology. 2001;34:494-501.
115. Pelli N, Fensom AH, Slade C, et al. Argininosuccinate lyase: a new autoantigen in liver disease. Clin Exp Immunol. 1998;114:455-461.
116. Bianchi FB, Muratori P, Muratori L. New autoantibodies and autoantigens in autoimmune hepatitis. Clin Liver Dis. 2002;6:785-797.
117. Martini E, Abuaf N, Cavalli F, et al. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology. 1988;8:1662-1666.
118. Abuaf N, Johanet C, Chretien P, et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology. 1992;16:892-898.
119. Muratori L, Cataleta M, Muratori P, et al. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut. 1998;42:721-726.
120. Han S, Tredger M, Gregorio GV, et al. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology. 1995;21:58-62.
121. Courvalin JC, Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis. 1997;17:79-90.
122. Courvalin JC, Lassoued K, Bartnik E, et al. The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. J Clin Invest. 1990;86:279-285.
123. Courvalin JC, Lassoued K, Worman HJ, et al. Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis. J Exp Med. 1990;172: 961-967.
124. Muratori P, Muratori L, Cassani F, et al. Anti-multiple nuclear dots (anti-MND) and anti-Sp100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol. 2002;127:172-175.
125. Muratori P, Muratori L, Ferrari R, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gasroenterol. 2003;98:431-437.
126. Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology. 1997;26:1054-1066.
127. Philipp T, Durazzo M, Trautwein C, et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet. 1994;344:578-581.
128. Mohan CH, Adams S, Stanik V, et al. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med. 1993; 177:1367-1381.
129. Burlingame RW, Boey ML, Starkebaum G, et al. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest. 1994;94:184-192.
130. Amoura Z, Koutouzov S, Piette J-C. The role of nucleosomes in lupus. Curr Opin Rheumatol. 2000;12:369-373.
131. Amoura Z, Chabre H, Koutouzov S, et al. Nucleosome-restricted antibodies are detected before anti-dsDNA and/or anti-histone antibodies in serum of MRL-MP lpr/lpr and +/+ mice and are present in kidney eluates. Arthritis Rheum. 1994;37:1684-1688.
132. Li L, Chen M, Huang DY, et al. Frequency and significance of antibodies to chromatin in autoimmune hepatitis type 1. J Gastroenterol Hepatol. 2000;15:1176-1182.
133. Czaja AJ, Shums Z, Binder WL, et al. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci. (in press)
134. Ohana M, Okazaki K, Hajiro K, et al. Antilactoferrin antibodies in autoimmune liver diseases. Am J Gastroenterol. 1998;93:1334-1339.
135. Norman GL. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease. Clin Applied Immunol Rev. 2001;2:45-63.
136. Reddy KR, Colombel JF, Poulain D, et al. Anti-S. cerevisiae antibodies in autoimmune liver disease. Am J Gastroenterol. 2001;96:252-253.
137. Porta G, Da Costa Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Ped Gastroenterol Nutrition. 1990;11:138-140.
138. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol. 1994;21: 866-871.
139. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938.
140. Czaja AJ, Carpenter HA, Santrach PJ, et al. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology. 1993; 104:1755-1761.
141. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med. 1996;125:588-598.
142. Gonazalez-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 2001;7:302-310.
143. Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet. 1998;353:409-413.
144. Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl. 2002;8:505-513.
145. Salcedo M, Vaquero J, Banares R, et al. Response to steroids in de novo autoimmune hepatitis after transplantation. Hepatology. 2002;35:349-356.